Recombinant activated factor VII in approved indications: Update on safety
- 13 July 2018
- journal article
- letter
- Published by Wiley in Haemophilia
- Vol. 24 (4) , E275-E277
Abstract
No abstract availableFunding Information
- Novo Nordisk
This publication has 6 references indexed in Scilit:
- Emicizumab Prophylaxis in Hemophilia A with InhibitorsNew England Journal of Medicine, 2017
- Treatment and Prevention of Bleeds in Haemophilia Patients with Inhibitors to Factor VIII/IXJournal of Clinical Medicine, 2017
- Safety update on the use of recombinant activated factor VII in approved indicationsBlood Reviews, 2015
- Advances in bypassing agent therapy for hemophilia patients with inhibitors to close care gaps and improve outcomesTherapeutic Advances in Drug Safety, 2011
- Recombinant factor VIIa: review of efficacy, dosing regimens and safety in patients with congenital and acquired factor VIII or IX inhibitorsJournal of Thrombosis and Haemostasis, 2004
- Safety profile of recombinant factor VIIaSeminars in Hematology, 2004